Kareem Hashir, Sahu Devavrata, Rao Mugula Sudhakar, Devasia Tom
Associate Professor, Department of Cardiology, KMC Manipal University, Manipal, Karnataka, India.
Junior Resident, Department of Cardiology, KMC Manipal University, Manipal, Karnataka, India.
J Clin Diagn Res. 2017 Mar;11(3):FD01-FD02. doi: 10.7860/JCDR/2017/24491.9359. Epub 2017 Mar 1.
Statins are safe, well tolerated, efficient and time tested drugs for the management of hypercholesterolemia, and thus play a cardinal role in the management of patients with heart disease. Although safe in clinical practice, they are associated with adverse effects, clinically the most important and most severe being muscle related complications/myotoxicity. Rhabdomyolysis, though rare, is the most severe form of myotoxicity. The US Food and Drug Administration (USFDA) adverse event reporting system reports rate of statin induced rhabdomyolysis at 0.3-13.5 cases per 1,000,000 patients. We present a case of a 74-year-old male who presented with an acute coronary syndrome and was initiated on atorvastatin. However, patient developed atorvastatin induced rhabdomyolysis, with non oliguric renal failure, which subsequently improved on cessation of medication.
他汀类药物安全、耐受性良好、疗效显著且久经考验，是治疗高胆固醇血症的药物，因此在心脏病患者的治疗中起着关键作用。虽然在临床实践中是安全的，但它们也会产生不良反应，临床上最重要且最严重的是与肌肉相关的并发症/肌毒性。横纹肌溶解症虽然罕见，但却是最严重的肌毒性形式。美国食品药品监督管理局（USFDA）不良事件报告系统报告的他汀类药物诱发横纹肌溶解症的发生率为每100万患者中有0.3 - 13.5例。我们报告一例74岁男性患者，该患者因急性冠状动脉综合征开始服用阿托伐他汀。然而，患者出现了阿托伐他汀诱发的横纹肌溶解症，并伴有非少尿性肾衰竭，随后在停药后病情有所改善。
